Beaumont ACO
A Physician/Health System Partnership

January 2022

Statin Therapy Measures Tip Sheet

Statin Therapy for Pts with Diabetes (SPD)

Measure Description: The % of patients 40-75yrs with a diagnosis of Diabetes during the measurement year who do not have Atherosclerotic Cardiovascular Disease (ASCVD).
Measure Goal: Dispensed at least one statin therapy of any intensity during the measurement year.
Inclusion Criteria: Patient medical claim and or pharmacy data. Any LDL result is inclusive.

Statin Therapy for Pts with Cardiovascular Disease (SPC)

Measure Description: The % of males 21-75yrs and females 40-75yrs with a diagnosis Atherosclerotic Cardiovascular Disease (ASCVD).
Measure Goal: Dispensed at least one statin therapy of moderate or high intensity during the measurement year.
Inclusion Criteria: Patient with MI, CABG, PCI, or diagnosis of Ischemic Vascular Disease (IVD). Any LDL result is inclusive.

Statin Use for Pts with Diabetes (SUPD)

Measure Description: The % of Medicare patients 40-75yrs with a diagnosis of Diabetes.
Measure Goal: Dispensed at least one statin therapy med of any intensity during the measurement year.
Inclusion Criteria: Patient medical pharmacy claim data only (at least 2 diabetes medication fills)
Exclusions: ESRD or Hospice.

Moderate Intensity Statin	
Name of Drug	**Dosage**
Atorvastatin	10-20 mg
Amlodipine-atorvastatin	10-20 mg
Ezetimibe-simvastatin	20-40 mg
Fluvastatin	40-80 mg
Lovastatin	40 mg
Pitavastatin	2-4 mg
Pravastatin	40-80 mg
Rosuvastatin	5-10 mg
Simvastatin	20-40 mg

High Intensity Statin	
Name of Drug	**Dosage**
Atorvastatin	40-80 mg
Amlodipine-atorvastatin	40-80 mg
Ezetimibe-simvastatin	80 mg
Rosuvastatin	20-40 mg
Simvastatin	80mg

Codes to submit for Statin Intolerance (Use for SPD & SPC only)

Exclusion Criteria: Cirrhosis, Myalgia, Myositis, Myopathy, Rhabdomyolysis, ESRD, Pregnant, ≥66 living in institutional or SNF setting, ≥81 with frailty claim, dispensed dementia medication and hospice.

Cirrhosis	Muscular Pain & Disease	End Stage Renal Disease
K70.30 Alcoholic cirrhosis of liver w/o ascites	**G72.0** Drug induced myopathy	**N18.5** Chronic Kidney Disease, stage 5
K70.31 Alcoholic cirrhosis of liver w/ascites	**G72.2** Myopathy due to other toxic agents	**N18.6** End Stage Renal Disease
K71.7 Toxic liver w/fibrosis & cirrhosis of liver	**G72.9** Myopathy, unspecified	**Z99.2** Dependence on Renal Dialysis
K74.3 Primary biliary cirrhosis	**M60.80** Other myositis, unspecified site	
K74.4 Secondary biliary cirrhosis	**M60.89** Other myositis, multiple sites	
K74.5 Biliary cirrhosis, unspecified	**M60.9** Myositis, unspecified	
K74.60 Unspecified cirrhosis of liver	**M62.82** Rhabdomyolysis	
K74.69 Other cirrhosis of liver	**M79.1** Myalgia	
P78.81 Congenital cirrhosis (of liver)	**M79.10** Myalgia, unspecified site	
K70.0 Alcoholic fatty liver	**M79.18** Myalgia, other site	
K70.9 Alcoholic liver disease unspecified	**G72.89** Other specified myopathies	
	T46.6X5A Adverse effect of Antihyperlipidemic & antiarteriosclerotic drug initial encounter	